Latest Breaking News On - Advanced accelerator - Page 1 : comparemela.com

FDA approves Lutathera for children with gastroenteropancreatic neuroendocrine tumors

FDA approves Lutathera for children with gastroenteropancreatic neuroendocrine tumors
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesBydrew amorosiTheodorew laetschMindy valcarcelAdvanced acceleratorDevelopmental therapeutics programPublished april

FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

United statesTheodore laetschTina deignanDevelopmental therapeutics programOlivier le moalEvaluate safetyAdolescent patients withAdvanced acceleratorTherapeutic area headMet primary endpointsProgression free survivalGastroenteropancreatic neuroendocrine

Lantheus Sued by Novartis Entities for Patent Infringement

By Adriano Marchese Lantheus Holdings is being sued by Swiss multinational pharmaceutical Novartis for patent infringement on a generic drug to treat.

United statesAdriano marcheseExchange commissionLantheus holdingsLantheus medical imagingAdvanced accelerator applications united statesAdvanced acceleratorArticle normalCancer drugsMedical equipment suppliesHealthcare life sciencesMedical diagnostic equipment suppliesSpecialized drugs medicationsMedical devices apparatusDiagnostic therapeutic devicesCorporate crime legal action

177Lu-Dotatate Prolongs PFS vs High-Dose Octreotide in GEP-NETs

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

Advanced accelerator177lu dotatateGep netsGastroenteropancreatic neuroendocrine tumorsNeuroendocrine tumorsLutetium lu 177 dotatateSomatostatin analogPhase 3 netter 2 trial2024 gastrointestinal cancers symposiumAsco giSimron singhSunnybrook health sciences centre

Radiopharmaceuticals for cancer: Making radiation precise

BioPharma

United statesWaals gewestAtonco pharmaFaisal khurshidRayze bioEmanuele ostuniMemorial sloan kettering cancer centerBristol myers squibbAtlas ventureJohns hopkins university school of medicineAblaze pharmaceuticalsMerck coUniversity of connecticutFusion pharmaceuticalsIdec pharmaceuticalsLife sciences